This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Celgene Corporation, USA.
Reference
Wu JJ, et al. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Advances in Therapy : 5 Mar 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01262-9
Rights and permissions
About this article
Cite this article
Apremilast less costly in biologic-naïve patients with psoriatic arthritis. PharmacoEcon Outcomes News 849, 3 (2020). https://doi.org/10.1007/s40274-020-6654-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6654-3